Vixtimotamab

DB17393InvestigationalProtein Based Therapies

Vixtimotamab: Overview.

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33 and T-cell surface glycoprotein CD3
Curator reviewed
Code names: AMV-564 · CNTO-3953 · T-652

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vixtimotamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.